Medicus Pharma Ltd.
No enriched coverage for $MDCX in the last 7 days.
No SEC Form 4 filings for $MDCX in the last 30 days.
See all $MDCX insider activity →Medicus Pharma (NASDAQ: MDCX) is shifting its focus to oncology, prioritizing CD228V for cancer therapy. The company has raised $90M in 3 years and aims to limit future financing needs through partnerships. It is also advancing SkinJect for rare skin disorders and Teverelix for urology and women's health. The strategy follows stock volatility and aims to demonstrate clinical progress.
Medicus Pharma (MDCX) outlined its strategy to advance clinical and regulatory milestones, focusing on partnerships and licensing deals. The company's pipeline includes CD228V for melanoma and other cancers, and SkinJect for Gorlin syndrome. Medicus has raised $90M to support development and operations, according to the shareholder update.
Medicus Pharma (MDCX) shares dropped 24.22% in after-hours trading to $0.12 after announcing a 50-to-1 share consolidation. The move, effective Oct. 12, aims to boost share price and comply with Nasdaq's minimum bid requirement. Shareholders' positions will be adjusted automatically. The company's market cap is $10.07 million, with shares down 93.49% over the past year.
Recent MDCX coverage spans corporate actions, financial news and regulation.
The shift may increase investor uncertainty and short-term pressure while the company seeks partnerships.
The announcement of new clinical milestones could boost investor confidence in MDCX.
The consolidation will reduce share count and may improve bid price compliance, but short‑term pressure from dilution and cash‑in‑lieu for fractions is expected.
The consolidation will reduce share count and raise the per‑share price, potentially improving Nasdaq compliance and supporting the stock price.
Consolidation should lift the share price and improve liquidity, but may cause short‑term volatility as fractional shares are cashed out.
AlphAI scores every news story that mentions MDCX with an AI model for sentiment and relevance, and aggregates insider trades from Medicus Pharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medicus Pharma (NASDAQ: MDCX) is shifting its focus to oncology, prioritizing CD228V for cancer therapy. The company has raised $90M in 3 years and aims to limit future financing needs through partnerships. It is also advancing SkinJect for rare skin disorders and Teverelix for urology and women's health. The strategy follows stock volatility and aims to demonstrate clinical progress.
2 min readMedicus Pharma (MDCX) outlined its strategy to advance clinical and regulatory milestones, focusing on partnerships and licensing deals. The company's pipeline includes CD228V for melanoma and other cancers, and SkinJect for Gorlin syndrome. Medicus has raised $90M to support development and operations, according to the shareholder update.
2 min readMedicus Pharma (MDCX) shares dropped 24.22% in after-hours trading to $0.12 after announcing a 50-to-1 share consolidation. The move, effective Oct. 12, aims to boost share price and comply with Nasdaq's minimum bid requirement. Shareholders' positions will be adjusted automatically. The company's market cap is $10.07 million, with shares down 93.49% over the past year.
2 min readMedicus Pharma (MDCX) plans a 50-for-1 share consolidation on October 12, 2026, to meet Nasdaq's minimum bid price requirement. Each 50 shares will convert to one, with fractional shares rounded down and compensated. The ticker and company name remain unchanged.
1 min readMedicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Share Consolidation Medicus Pharma Ltd. (the "Company") today announced that it will effect a fifty-to-one consolidation (the "Share Consolidation") of the Company's common shares, no par value (the "Common Shares"), to be effective on October 12, 2026. Th
1 min readMedicus Pharma (MDCX) proposed a redesigned trial for its prostate cancer drug Teverelix, aiming to cut enrollment by 60% and position it for licensing. The company submitted a Phase 2b/3 protocol to the FDA, seeking to reduce development time and costs. The FDA has not yet agreed to the proposed pathway. Medicus plans to use the feedback to attract a pharmaceutical partner.
2 min readMedicus Pharma (MDCX) submitted a Phase 2b/3 trial design for Teverelix to the FDA, aiming to reduce the patient count from 1,500 to 600. The trial focuses on prostate cancer patients with cardiovascular risk. The company seeks a strategic partner for the program, with clinical readiness expected by year-end. FDA approval is not guaranteed, and no licensing deal is assured.
2 min readMedicus Pharma (MDCX) will focus its SkinJect asset development on Gorlin syndrome patients with multiple basal cell carcinoma lesions, abandoning other indications. The shift follows regulatory feedback and commercial assessments, aiming to resolve FDA concerns. The U.S. market for Gorlin syndrome treatments is estimated at $1.1 billion, with potential peak revenues of $383 million. MDCX shares fell 2.23% premarket on Monday.
2 min readMedicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement. On September 11, 2026, Medicus Pharma Ltd. (the "Company") and YA II PN, LTD. ("Yorkville") mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, between the Company and Yorkvi
1 min readMedicus Pharma (MDCX) reported progress in its SkinJect program, confirming a 200-microgram patch dose for further studies. The company is focusing on Gorlin syndrome and seeking a partner for nodular basal cell carcinoma. A potential partnership could bring $25,000+ in reimbursement. Additionally, MDCX is collaborating with Pfizer on a CD228-targeted antibody-drug conjugate for melanoma and solid tumors, receiving $2M in funding.
2 min read
